

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

IGFBP-3, Total Antibody Pair Kit

RRID:AB_2783671

Type: Antibody

Proper Citation

Ansh Labs Cat# AL-120, RRID:AB_2783671

Antibody Information

URL: http://antibodyregistry.org/AB_2783671

Proper Citation: Ansh Labs Cat# AL-120, RRID:AB_2783671

Target Antigen: IGFBP-3

Clonality: monoclonal

Comments: Applications: ELISA

Antibody Name: IGFBP-3, Total Antibody Pair Kit

Description: This monoclonal targets IGFBP-3

Target Organism: human

Antibody ID: AB_2783671

Vendor: Ansh Labs

Catalog Number: AL-120

Record Creation Time: 20231110T032958+0000

Record Last Update: 20260829T080139+0000

Ratings and Alerts

No rating or validation information has been found for IGFBP-3, Total Antibody Pair Kit.

No alerts have been found for IGFBP-3, Total Antibody Pair Kit.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bøtkjær JA, et al. (2024) Dynamics of IGF signalling during the ovulatory peak in women undergoing ovarian stimulation. The Journal of clinical endocrinology and metabolism.

Barrios V, et al. (2024) Reduction in Pappalysin-2 Levels and Lower IGF-I Bioavailability in Female Adolescents With Anorexia Nervosa. The Journal of clinical endocrinology and metabolism, 109(3), e920.

Güemes M, et al. (2024) Implication of Pappalysins and Stanniocalcins in the Bioavailability of IGF-I in Children With Type 1 Diabetes Mellitus. Journal of the Endocrine Society, 8(6), bvae081.

Martín-Rivada Á, et al. (2024) Prepubertal children with obesity have high free IGF-1 levels and accelerated growth despite reduced pappalysin levels. The Journal of clinical endocrinology and metabolism.

Barrios V, et al. (2023) Increased IGFBP proteolysis, IGF-I bioavailability and pappalysin levels in children with Prader-Willi syndrome. The Journal of clinical endocrinology and metabolism.